Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Other ICR Research
  • View item
  • Home
  • ICR Divisions
  • Other ICR Research
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Treatment of relapsed Wilms tumors: lessons learned

Thumbnail
Date
2009-12
ICR Author
Pritchard-Jones, Kathy
Author
Spreafico, F
Jones, KP
Malogolowkin, MH
Bergeron, C
Hale, J
de Kraker, J
Dallorso, S
Acha, T
de Camargo, B
Dome, JS
Graf, N
Show allShow less
Type
Journal Article
Metadata
Show full item record
Abstract
Treatment regimens for recurrent Wilms tumor (WT) are currently designed to include drugs that are not used during primary chemotherapy, using a risk-stratified approach. Therapy of recurrent disease depends on the nature of initial treatment, and of recognized prognostic indicators inherent in the primary tumor. Several highly effective chemotherapy regimens, including ifosfamide-carboplatin-etoposide, cyclophosphamide-etoposide and carboplatin-etoposide, are considered first treatment choice for recurrent disease. While intense-dose chemotherapy is uniformly accepted to treat high-risk recurrent WTs, the optimal therapy for standard-risk children has yet to be defined, owing to the small number of such patients and their relatively better prognosis compared with high-risk recurrences. Recurrent tumors among those defined as very-high risk are likely to develop chemoresistant disease, and novel therapeutic strategies will be necessary to cure these patients. Evidence on how to properly administer surgery and radiotherapy at relapse is more fragmentary. The authors have reviewed the available experiences concerning the treatment of recurrent WT, and have attempted to provide the most up-to-date recommendations regarding the optimal risk-based treatment for these patients.
URI
https://repository.icr.ac.uk/handle/internal/2403
DOI
https://doi.org/10.1586/ERA.09.159
Collections
  • Other ICR Research
Language
eng
License start date
2009-12
Citation
EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 pp. 1807 - 1815
Publisher
EXPERT REVIEWS

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.